Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

BACKGROUND: Neoadjuvant endocrine therapy with an aromatase inhibitor has shown efficacy comparable to that of neoadjuvant chemotherapy in patients with postmenopausal breast cancer. Preclinical and clinical studies have shown that the antidiabetic drug metformin has anti-tumor activity. This prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jisun, Lim, Woosung, Kim, Eun-Kyu, Kim, Min-Kyoon, Paik, Nam-Sun, Jeong, Sang-Seol, Yoon, Jung-han, Park, Chan Heun, Ahn, Sei Hyun, Kim, Lee Su, Han, Sehwan, Nam, Seok Jin, Kang, Han-Sung, Kim, Seung Il, Yoo, Young Bum, Jeong, Joon, Kim, Tae Hyun, Kang, Taewoo, Kim, Sung-Won, Jung, Yongsik, Lee, Jeong Eon, Kim, Ku Sang, Yu, Jong-Han, Chae, Byung Joo, Jung, So-Youn, Kang, Eunyoung, Choi, Su Yun, Moon, Hyeong-Gon, Noh, Dong-Young, Han, Wonshik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984742/
https://www.ncbi.nlm.nih.gov/pubmed/24612502
http://dx.doi.org/10.1186/1471-2407-14-170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984742/
https://www.ncbi.nlm.nih.gov/pubmed/24612502
http://dx.doi.org/10.1186/1471-2407-14-170

Ejemplares similares